Chris Baldwin

Summary

Publications

  1. ncbi HIV-1 drug-resistance and drug-dependence
    Chris Baldwin
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, The Netherlands
    Retrovirology 4:78. 2007
  2. ncbi Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant
    Chris Baldwin
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    J Virol 82:7735-40. 2008
  3. ncbi Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution
    Ilja Bontjer
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, Meibergdreef 15 K3 105, 1105 AZ Amsterdam, The Netherlands
    J Virol 83:368-83. 2009

Collaborators

Detail Information

Publications3

  1. ncbi HIV-1 drug-resistance and drug-dependence
    Chris Baldwin
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, The Netherlands
    Retrovirology 4:78. 2007
    ..Second, a compensatory mutation that repairs the protein function, but in the presence of the drug, which becomes an intrinsic part of the mechanism. The clinical relevance of drug-dependent HIV-1 variants is also discussed...
  2. ncbi Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant
    Chris Baldwin
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    J Virol 82:7735-40. 2008
    ..In this study, we set out to critically test this mechanistic explanation with alternative effectors that may control the Env switch, including other fusion inhibitors and antibodies that target gp41...
  3. ncbi Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution
    Ilja Bontjer
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, Meibergdreef 15 K3 105, 1105 AZ Amsterdam, The Netherlands
    J Virol 83:368-83. 2009
    ..In general, virus evolution may provide a powerful tool to optimize Env vaccine antigens...